Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: GlobeNewswire
– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 – – Ongoing Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is anticipated to deliver topline data in Q4 2024 to Q1 2025 – – Conference call today at 8:30 a.m. ET – RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results for the first quarter ending March 31, 2024, and provided a corporate update. “We continue to execute on our strategy and advance our pivotal clinical trials of lorundrostat for the treatment of hypertension. Enrollment in these trials is ongoing and we look forward to annou
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics to Participate in the Bank of America Securities Health Care ConferenceGlobeNewswire
- Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024GlobeNewswire
MLYS
Earnings
- 5/9/24 - Miss
MLYS
Sec Filings
- 5/15/24 - Form 4
- 5/10/24 - Form 4
- 5/9/24 - Form 144
- MLYS's page on the SEC website